JBCHEPHARM - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.1
| Stock Code | JBCHEPHARM | Market Cap | 30,082 Cr. | Current Price | 1,876 ₹ | High / Low | 1,939 ₹ |
| Stock P/E | 41.4 | Book Value | 238 ₹ | Dividend Yield | 0.83 % | ROCE | 25.9 % |
| ROE | 20.2 % | Face Value | 1.00 ₹ | DMA 50 | 1,833 ₹ | DMA 200 | 1,756 ₹ |
| Chg in FII Hold | -0.75 % | Chg in DII Hold | -0.12 % | PAT Qtr | 179 Cr. | PAT Prev Qtr | 200 Cr. |
| RSI | 53.3 | MACD | 11.3 | Volume | 68,152 | Avg Vol 1Wk | 1,89,053 |
| Low price | 1,303 ₹ | High price | 1,939 ₹ | PEG Ratio | 1.74 | Debt to equity | 0.01 |
| 52w Index | 90.0 % | Qtr Profit Var | 14.6 % | EPS | 46.5 ₹ | Industry PE | 29.0 |
📈 Chart & Trend Analysis: JBCHEPHARM is trading at ₹1,876, above both its 50 DMA (₹1,833) and 200 DMA (₹1,756), signaling strong technical positioning. RSI at 53.3 suggests neutral momentum, neither overbought nor oversold. MACD at 11.3 confirms bullish crossover, supporting upward bias. Bollinger Bands show price near the upper band, indicating positive momentum but with potential resistance. Current volume (68K) is below the 1-week average (189K), reflecting reduced participation despite bullish signals.
🔑 Momentum Signals: Short-term momentum is bullish with immediate support at ₹1,833 (DMA50) and major support at ₹1,756 (DMA200). Resistance lies at ₹1,920–₹1,940 (recent high zone). Optimal entry zone: ₹1,840–₹1,860. Exit zone: ₹1,920–₹1,940 for short-term traders. Trend status: Trending upward.
Positive ✅
- Strong ROCE (25.9%) and ROE (20.2%) highlight efficient capital use.
- Low debt-to-equity (0.01) ensures financial stability.
- Dividend yield of 0.83% adds investor appeal.
- EPS of ₹46.5 reflects consistent profitability base.
Limitation ⚠️
- High P/E (41.4) compared to industry PE (29.0) suggests overvaluation.
- PEG ratio of 1.74 indicates valuation is stretched relative to growth.
- Volume trend weaker than average, showing lack of strong buying support.
Company Negative News 📉
- FII holding decreased (-0.75%), showing reduced foreign investor confidence.
- DII holding also slipped (-0.12%), reflecting cautious domestic sentiment.
- PAT declined to ₹179 Cr from ₹200 Cr, showing earnings pressure.
Company Positive News 📊
- Quarterly profit variation of 14.6% indicates operational resilience.
- Strong 52-week performance index at 90% highlights relative strength.
Industry 🌐
- Industry PE at 29.0 is lower than JBCHEPHARM’s PE of 41.4, suggesting sector peers may be more attractively valued.
- Pharma sector outlook remains positive with demand-driven growth opportunities.
Conclusion 📝
JBCHEPHARM is currently trending upward, supported by strong fundamentals and technical positioning above key moving averages. While valuation appears stretched, low debt and consistent profitability provide stability. Risk-tolerant traders may consider entries near ₹1,840–₹1,860 with exits around ₹1,920–₹1,940, while long-term investors should monitor volume trends and earnings growth for sustained momentum.
Would you like me to also prepare a peer benchmarking overlay comparing JBCHEPHARM with pharma peers like Divi’s Lab, Torrent Pharma, and Alkem Labs to highlight relative strength and valuation?